Decentralized Trial Growth Curavit has demonstrated rapid expansion in decentralized trial capabilities with recent HEOR services launch, signaling strong opportunity to cross-sell digital therapeutic trial support and real-world evidence services to sponsors pursuing remote trial models.

HEOR Expansion Recent press indicates Curavit is formalizing Health Economics and Outcomes Research offerings, aligning with pharmaceutical sponsors’ need for value demonstrations in digital therapeutics, creating a pathway to tiered service packages around outcomes and cost-effectiveness.

Scale Enrolment Capability Position Curavit as the partner for faster, more predictable enrollment and better participant retention at national scale, offering a compelling value proposition to sponsors facing enrollment bottlenecks and fragmented data management.

Hybrid Collaboration Emphasize interoperability with existing CROs, sites, and study infrastructure to attract sponsors seeking a flexible, additive solution that compliments current operations rather than replaces them.

Financial Footing With a reported revenue range and a $5M Series A funding round, Curavit presents a credible growth story and potential for tiered engagement models; target mid-market biopharma and digital therapeutics firms aiming for scalable remote trial execution.